FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128490347> ?p ?o ?g. }

• W2128490347 endingPage "3079" @default.
• W2128490347 startingPage "3070" @default.
• W2128490347 abstract "PURPOSE To evaluate long-term cardiac function in patients without disease who had received six cycles of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2) (FEC 50) or the same regimen with epirubicin 100 mg/m(2) (FEC 100) as adjuvant chemotherapy for node-positive breast cancer in the French Adjuvant Study Group-05 trial. PATIENTS AND METHODS One hundred fifty patients (FEC 50, n = 65; FEC 100, n = 85) who were without disease and who gave their informed consent were enrolled for long-term cardiac assessment. The assessment included cardiac events occurring after the end of chemotherapy, vital signs, concomitant disease, ECG, isotopic left ventricular ejection fraction (LVEF), and echographic parameters. Abnormal files were blindly reviewed by cardiologists and oncologists. Results The median follow-up time was 102 months. After FEC 100, LVEF was less than 50% in five patients (radioisotopic method), and two patients experienced congestive heart failure (CHF) that was possibly related to treatment. Asymptomatic left ventricular dysfunction (LVD) was experienced in 18 patients after FEC 100 and in one patient after FEC 50. In these patients, treatment causality was probable in eight patients. Two additional years after this assessment, all 18 patients were still asymptomatic. CONCLUSION After more than 8 years of follow-up, the cardiac toxicity observed after adjuvant treatment with FEC 100 comprised two cases of well-controlled CHF and 18 cases of asymptomatic LVD. In the majority of women with primary breast cancer, the benefits of treatment with FEC 100 in terms of disease-free and overall survival outweigh the risks, and cardiac risk factors should be carefully evaluated in patient selection." @default.
• W2128490347 created "2016-06-24" @default.
• W2128490347 creator A5006109406 @default.
• W2128490347 creator A5010128152 @default.
• W2128490347 creator A5012391914 @default.
• W2128490347 creator A5012804079 @default.
• W2128490347 creator A5017495356 @default.
• W2128490347 creator A5024118579 @default.
• W2128490347 creator A5033187481 @default.
• W2128490347 creator A5038734791 @default.
• W2128490347 creator A5039923190 @default.
• W2128490347 creator A5052648400 @default.
• W2128490347 creator A5071336106 @default.
• W2128490347 creator A5079214434 @default.
• W2128490347 creator A5080896131 @default.
• W2128490347 creator A5086724383 @default.
• W2128490347 date "2004-08-01" @default.
• W2128490347 modified "2023-10-17" @default.
• W2128490347 title "Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group" @default.
• W2128490347 cites W12356482 @default.
• W2128490347 cites W1262485082 @default.
• W2128490347 cites W1492360552 @default.
• W2128490347 cites W1796787464 @default.
• W2128490347 cites W1828224642 @default.
• W2128490347 cites W1875233875 @default.
• W2128490347 cites W1896390601 @default.
• W2128490347 cites W1969262864 @default.
• W2128490347 cites W1987593270 @default.
• W2128490347 cites W2022361916 @default.
• W2128490347 cites W2044934343 @default.
• W2128490347 cites W2049129583 @default.
• W2128490347 cites W2058337944 @default.
• W2128490347 cites W2058563509 @default.
• W2128490347 cites W2091744994 @default.
• W2128490347 cites W2096254008 @default.
• W2128490347 cites W2111426313 @default.
• W2128490347 cites W2122316200 @default.
• W2128490347 cites W2125987430 @default.
• W2128490347 cites W2136867800 @default.
• W2128490347 cites W2142399979 @default.
• W2128490347 cites W2153778647 @default.
• W2128490347 cites W2183288147 @default.
• W2128490347 cites W2313677237 @default.
• W2128490347 cites W4230454151 @default.
• W2128490347 cites W4234837271 @default.
• W2128490347 cites W4244497714 @default.
• W2128490347 doi "https://doi.org/10.1200/jco.2004.03.098" @default.
• W2128490347 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15284257" @default.
• W2128490347 hasPublicationYear "2004" @default.
• W2128490347 type Work @default.
• W2128490347 sameAs 2128490347 @default.
• W2128490347 citedByCount "87" @default.
• W2128490347 countsByYear W21284903472012 @default.
• W2128490347 countsByYear W21284903472013 @default.
• W2128490347 countsByYear W21284903472014 @default.
• W2128490347 countsByYear W21284903472015 @default.
• W2128490347 countsByYear W21284903472016 @default.
• W2128490347 countsByYear W21284903472017 @default.
• W2128490347 countsByYear W21284903472018 @default.
• W2128490347 countsByYear W21284903472019 @default.
• W2128490347 countsByYear W21284903472020 @default.
• W2128490347 countsByYear W21284903472021 @default.
• W2128490347 countsByYear W21284903472022 @default.
• W2128490347 crossrefType "journal-article" @default.
• W2128490347 hasAuthorship W2128490347A5006109406 @default.
• W2128490347 hasAuthorship W2128490347A5010128152 @default.
• W2128490347 hasAuthorship W2128490347A5012391914 @default.
• W2128490347 hasAuthorship W2128490347A5012804079 @default.
• W2128490347 hasAuthorship W2128490347A5017495356 @default.
• W2128490347 hasAuthorship W2128490347A5024118579 @default.
• W2128490347 hasAuthorship W2128490347A5033187481 @default.
• W2128490347 hasAuthorship W2128490347A5038734791 @default.
• W2128490347 hasAuthorship W2128490347A5039923190 @default.
• W2128490347 hasAuthorship W2128490347A5052648400 @default.
• W2128490347 hasAuthorship W2128490347A5071336106 @default.
• W2128490347 hasAuthorship W2128490347A5079214434 @default.
• W2128490347 hasAuthorship W2128490347A5080896131 @default.
• W2128490347 hasAuthorship W2128490347A5086724383 @default.
• W2128490347 hasBestOaLocation W21284903471 @default.
• W2128490347 hasConcept C121608353 @default.
• W2128490347 hasConcept C126322002 @default.
• W2128490347 hasConcept C141071460 @default.
• W2128490347 hasConcept C2776694085 @default.
• W2128490347 hasConcept C2776755627 @default.
• W2128490347 hasConcept C2777910003 @default.
• W2128490347 hasConcept C2778198053 @default.
• W2128490347 hasConcept C2779384505 @default.
• W2128490347 hasConcept C2780456651 @default.
• W2128490347 hasConcept C2780835546 @default.
• W2128490347 hasConcept C2781413609 @default.
• W2128490347 hasConcept C530470458 @default.
• W2128490347 hasConcept C71924100 @default.
• W2128490347 hasConcept C78085059 @default.
• W2128490347 hasConceptScore W2128490347C121608353 @default.
• W2128490347 hasConceptScore W2128490347C126322002 @default.
• W2128490347 hasConceptScore W2128490347C141071460 @default.
• W2128490347 hasConceptScore W2128490347C2776694085 @default.
• W2128490347 hasConceptScore W2128490347C2776755627 @default.

• next